We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy.
- Authors
Brar, Gagandeep; Greten, Tim F.; Brown, Zachary J.
- Abstract
Hepatocellular carcinoma (HCC) is a major cause of cancer-associated mortality worldwide and is expected to rise. Patients with early-stage disease may have a good prognosis with a 5-year survival rate of greater than 70%. However, the majority of patients are diagnosed with late-stage disease with a dismal overall survival rate of less than 16%. Therefore, there is a great need for advances in the treatment of advanced HCC, which for approximately the past decade, has been sorafenib. Immunotherapy is an evolving cancer treatment and has shown promise in treating patients with advanced HCC. In this review, we discuss the current standard of care for advanced HCC and then discuss the evolving role of immunotherapies.
- Publication
Therapeutic Advances in Gastroenterology, 2018, Vol 11, p1
- ISSN
1756-283X
- Publication type
Article
- DOI
10.1177/1756284818808086